Rebound Seen Predelivery After HIV Suppression in Pregnancy

Share this content:
Rebound Seen Predelivery After HIV Suppression in Pregnancy
Rebound Seen Predelivery After HIV Suppression in Pregnancy

FRIDAY, Aug. 11, 2017 (HealthDay News) -- Women achieving HIV viral suppression in pregnancy can experience viral load rebound predelivery, according to a study published in the September issue of Obstetrics & Gynecology.

Isabelle Boucoiran, M.D., from the University of British Columbia in Vancouver, Canada, and colleagues used a Canadian provincial perinatal HIV database (1997 to 2015) to identify patients who had a live birth, received combination antiretroviral therapy for at least four weeks, had viral load measured within one month of delivery, and had at least one previous undetectable viral load during pregnancy. Viral load rebound was defined as viral load >50 copies/mL (or >400 copies/mL for 1997 to 1998).

The researchers found that 318 of the 470 women in the database met inclusion criteria. Nineteen women (6 percent) had viral load rebound with a mean log10 viral load near delivery of 2.71 copies/mL (=513 copies/mL), while six women (32 percent) had a viral load above 1,000 copies/mL. In half of the women, rebound was detected within one day before delivery. Viral load rebound was significantly associated with aboriginal ethnicity, cocaine use, and hepatitis C virus polymerase chain reaction positivity. There were no HIV vertical transmissions.

"Even women attending for HIV care and achieving viral suppression in pregnancy can experience viral load rebound predelivery," the authors write.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »